Total metabolic tumor volume is effective for determining the prognosis of high-tumor-burden follicular lymphoma, according to an article published in the Journal of Clinical Oncology.1

Researchers analyzed data from 3 prospective trials containing baseline data of 185 enrolled patients receiving immunochemotherapy. The median age of enrolled patients was 55 years; 92% had stage III or IV follicular lymphoma.

Five-year overall progression-free survival was 55%; overall survival was 92%. Survival was inferior for patients with a total metabolic tumor volume of greater than 510 cm3; the 29% of patients in this group had a 5-year progression-free survival of 33%, and a 5-year overall survival of 85%.

Continue Reading

RELATED: Brentuximab Vedotin + AVD and ISRT Efficacious for Early Stage Hodgkin Lymphoma

The authors conclude that baseline total metabolic tumor volume is a strong independent prognostic tool, though if used in conjunction with the Follicular Lymphoma International Prognostic Index, patients at high risk of early progression can be identified.

Reference

  1. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a tooled analysis of three multicenter studies. J Clin Oncol. 2016 Aug 22. doi: 10.1200/JCO.2016.66.9440 [Epub ahead of print]

Topics:

Hematologic Cancers Lymphoma